<DOC>
	<DOC>NCT01619839</DOC>
	<brief_summary>NKTR-181 is being developed as an analgesic compound for the treatment of moderate to severe chronic pain - active as a mu agonist, but with inherent molecular properties designed to provide a unique clinical profile, including most notably, reduced CNS side effects and an attenuated attractiveness as a target of abuse.</brief_summary>
	<brief_title>A Phase 2 Study To Assess The Efficacy, Tolerability, And Safety OF NKTR-181 In Subjects With Chronic OA Knee Pain</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis, Knee</mesh_term>
	<criteria>Willing and able to give written informed consent; Willing and able to understand the study procedures, and comply with all study procedures; Females or males, age â‰¥ 18 years old; Body mass index 1839, inclusive; In good general health; Clinical diagnosis of OA in one or both knees; Have been on a stable regimen of pain medication for the management of OA knee pain; Not experiencing adequate pain relief with their current dosing regimen; Women of childbearing potential (WCBP) must agree to use highly effective methods of birth control. Male subjects must agree to use contraception. Females who are pregnant or lactating; Known history of hypersensitivity, intolerance, or allergy to opioids; Diagnosed as having any chronic pain symptom that in the Investigator's opinion would interfere with the assessment of pain and other symptoms of OA; Presence of any medical condition that would preclude study participation in the opinion of the investigator; Clinically significant abnormalities of vital signs or clinical laboratory results; Clinically significant electrocardiographic abnormalities; Received systemic corticosteroids within 30 days prior to signing the consent form; Subjects who are known or suspected to be currently abusing alcohol or drugs; Positive urine drug screen, or alcohol breath test during Screening Period testing; Positive serology for the surface antigen of Hepatitis B (HBsAg) or Hepatitis C (antiHCV) during Screening Period testing; Known to be human immunodeficiency virus (HIV) positive; Donation of blood or plasma within 30 days prior to signing the consent form; Participation in another drug or biologic study within 30 days prior to signing the consent form; Any other reason that, in the opinion of the Investigator or Medical Monitor, would render the subject unsuitable for participation in the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Nektar</keyword>
	<keyword>NKTR-181</keyword>
</DOC>